FUNDAMENTAL AND CLINICAL STUDIES ON AZTREONAM IN THE GYNECOLOGICAL FIELD

Aztreonam (AZT), a new monocyclic β-lactam antibiotic was studied on clinical efficacy for infectious disease in gynecological field. 1. At about 80 minutes following intravenous injection of 1g dose of AZT, it penetrated well into internal genital organs at therapeutic levels. Moreover it transfered very fast and enough into intrapelvic dead space exudate, and its level was kept still as high at 12 hours after administration. 2. AZT was given to 20 women affected with gynecological infectious disease. The outcome of AZT therapy was as follows: effective in 5 out of 6 patients (83.3%) administered intravenously and in all of 14 patients (100%) recieved intramuscularly. 3. Notable adverse effects or abnormal laboratory findings were not observed except 1 case of diarrhea and 2 cases of transient and slight elevation of serum CPK and transaminases. Based on these results, we may conclude that AZT is a highly effective and a very safe antibiotic for the treatment of infectious disease in gynecological field.